Researchers at the University Hospital of Salzburg’s EB House Austria are using a Tecan Spark® multimode reader to investigate epidermolysis bullosa (EB).
Researchers at the University Hospital of Salzburg’s EB House Austria are using a Tecan Spark® multimode reader to investigate epidermolysis bullosa (EB), a rare inherited disease that causes the skin to become ‘as fragile as a butterfly’s wings’, blistering in response to friction or trauma. Dr Verena Wally, group leader of small molecules research, explained: “The main aim of my group is to identify potential therapeutic targets for EB. This requires a variety of functional assays, including cell viability, proliferation, migration and invasion assays – as well as luminescence- and fluorescence-based studies.”
“We purchased a Spark reader in 2016 to support our research, and it has brought huge benefits to our workflow, saving time and freeing up personnel. For example, our Spark is equipped with the Gas Control Module (GCM™) and Live Viewer™, which offers us the functionality we need to automate migration assays, instead of taking pictures with a microscope and using cell counting software or counting them ourselves. Reproducibility has been a key advantage of the new platform, as the reader removes any user bias or human error. In addition, before the Spark, we were limited to taking measurements of time points when we were actually in the lab, but this could lead to us missing the time point that would actually be important. We can now leave the plate in the reader and take readings every few hours – gone are the days when if we missed the event, we had to start from the beginning.”
To find out more about live cell imaging, visit lifesciences.tecan.com/cellbiology
For research use only. Not for use in clinical diagnostics.
For more information please contact
Tecan Trading AG
Antonietta Allocca
Seestrasse 103, CH-8708 Männedorf
Tel +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2016, Tecan generated sales of CHF 506 million (USD 508 million; EUR 474 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
